Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 1.00 |
| ▸ | CYP1A1 | P04798 | 6/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 6/20 | 1.00 |
| ▸ | CYP1B1 | Q16678 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
| ▸ | CA12 | O43570 | 3/20 | 1.00 |
| ▸ | CA4 | P22748 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | CA7 | P43166 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | XDH | P47989 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | DPP4 | P27487 | 2/20 | 1.00 |
| ▸ | GSK3B | P49841 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hesperetin SCHEMBL6422865 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL5202121 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL29534477 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL39833 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL765368 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL30696626 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL29484563 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL31689737 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL20929082 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 | |
| Hesperetin SCHEMBL28595598 | 0.99 | CYP19A1 (0.98) | CYP19A1CYP1A1CYP1A2CYP1B1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 171 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025217418-A1 | SAMPLE PREPARATION FOR NUCLEIC ACIDS | Life Technologies Corporation (US) | 2025-10-16 | — | — | WO | claimed |
| WO-2025034736-A1 | SAMPLE PREPARATION FOR NUCLEIC ACIDS | Life Technologies Corporation (US) | 2025-02-13 | — | — | WO | claimed |
| CN-118996720-A | Medical elastic thread easy to shear and low in divergence | 微尔创（武汉）医疗科技有限公司 | 2024-11-22 | — | — | CN | claimed |
| US-20230090146-A1 | MICROEMULSIONS AND USES THEREOF TO DISPLACE OIL IN HETEROGENEOUS POROUS MEDIA | UNIVERSITY OF WYOMING | 2023-03-23 | — | — | US | claimed |
| WO-2022018376-A2 | ECOBIOLOGICAL FORMULATION, COMPATIBLE WITH CELL LIFE, USABLE IN THE COSMETIC, DERMOPHARMACEUTICAL OR VETERINARY FIELDS | NAOS INSTITUTE OF LIFE SCIENCE (FR) | 2022-01-27 | — | — | WO | claimed |
| US-12637560-B2 | Resin composition | DUPONT ELECTRONIC MATERIALS INTERNATIONAL, LLC (US) | 2026-05-26 | — | — | US | disclosed |
| EP-4729046-A2 | COMPOSITIONS HAVING ENHANCED DEPOSITION OF SURFACTANT SOLUBLE ANTIDANDRUFF AGENTS | The Procter & Gamble Company (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-3784352-B1 | COMPOSITIONS HAVING ENHANCED DEPOSITION OF SURFACTANT SOLUBLE ANTIDANDRUFF AGENTS | PROCTER & GAMBLE (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12557843-B2 | Other than cannabinoids, flavonoids, and terpenes | LARSON RAYMOND LOUIS (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260048108-A1 | CANCER THERAPY COMPOSITIONS AND USES THEREOF | HDT BIO CORP (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260041754-A1 | NANOPARTICLE COMPLEXES FOR ENHANCED SAFETY | HDT BIO CORP (US) | 2026-02-12 | — | — | US | disclosed |
| US-12485163-B2 | Cancer therapy compositions and uses thereof | HDT BIO CORP. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20220112321-A1 | HIGH REFRACTIVE INDEX MATERIALS | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2022-04-14 | — | — | US | disclosed |
| EP-3981806-A1 | HIGH REFRACTIVE INDEX MATERIALS | Rohm and Haas Electronic Materials LLC (US) | 2022-04-13 | — | — | EP | disclosed |
| CN-114316137-A | High refractive index materials | 罗门哈斯电子材料有限责任公司 | 2022-04-12 | — | — | CN | disclosed |
| US-11291616-B2 | Delivery of surfactant soluble anti-dandruff agent | THE PROCTER AND GAMBLE COMPANY (US) | 2022-04-05 | — | — | US | disclosed |
| CN-107530257-B | Delivery of surfactant soluble antidandruff agents | 宝洁公司 | 2022-03-29 | — | — | CN | disclosed |
| EP-3532013-B1 | HAIR COMPOSITIONS WITH INCREASED DEPOSITION OF ACTIVE AGENTS | PROCTER & GAMBLE (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-114072163-A | New material for healing skin wound and preventing scar | 芝加哥大学 | 2022-02-18 | — | — | CN | disclosed |
| WO-2022018376-A2 | ECOBIOLOGICAL FORMULATION, COMPATIBLE WITH CELL LIFE, USABLE IN THE COSMETIC, DERMOPHARMACEUTICAL OR VETERINARY FIELDS | NAOS INSTITUTE OF LIFE SCIENCE (FR) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11291616-B2 | Delivery of surfactant soluble anti-dandruff agent | SMURF1, SMURF2, POLR1C | CYP19A1 1706/4885CYP1A1 2991/4885CYP1A2 3418/4885 |
| US-12637560-B2 | Resin composition | TAF1, TAF11, TAF5 | CYP19A1 2571/4885CYP1A1 2337/4885CYP1A2 3802/4885 |
| US-20260048108-A1 | CANCER THERAPY COMPOSITIONS AND USES THEREOF | SLC11A2, CD47, PDCD1LG2 | CYP19A1 4389/4885CYP1A1 4860/4885CYP1A2 4838/4885 |
| US-20260041754-A1 | NANOPARTICLE COMPLEXES FOR ENHANCED SAFETY | ITGAL, ITGA2B, ITGA2 | CYP19A1 3714/4885CYP1A1 2657/4885CYP1A2 3698/4885 |
| US-12557843-B2 | Other than cannabinoids, flavonoids, and terpenes | CCT5, CNR2, CPNE4 | CYP19A1 2327/4885CYP1A1 932/4885CYP1A2 884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.